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Encephalopathy and altered higher mental functions
are common clinical complications of acute kidney
injury. Although sepsis is a major triggering factor,
acute kidney injury predisposes to confusion by
causing generalised inflammation, leading to
increased permeability of the blood–brain barrier,
exacerbated by hyperosmolarity and metabolic
acidosis due to the retention of products of nitrogen
metabolism potentially resulting in increased brain
water content. Downregulation of cell membrane
transporters predisposes to alterations in
neurotransmitter secretion and uptake, coupled with
drug accumulation increasing the risk of
encephalopathy. On the other hand, acute brain injury
can induce a variety of changes in renal function
ranging from altered function and electrolyte
imbalances to inflammatory changes in brain death
kidney donors.rohumeral changes that directly affect the kidney by in-Review
Acute kidney injury (AKI) is a worldwide problem, asso-
ciated with increasing morbidity and mortality, and can
be considered as a systemic inflammatory condition that
may have substantial effects on various distant organs
[1-3].
Patients with AKI commonly develop confusion, which
may be present at the onset of AKI or develop subse-
quently. The cause of neurological disturbance is often
multifactorial, as the majority of patients who develop
AKI do so on a background of small vessel disease asso-
ciated with cardiac failure, diabetes and hypertension –
resulting in a spectrum of fluctuating clinical signs
ranging from headache, visual abnormalities, tremor and
asterixis through to multifocal myoclonus, chorea, sei-
zures and coma. As such, many older patients who de-
velop AKI may already have established small vessel* Correspondence: andrewdavenport@nhs.net
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stated.ischaemic brain disease characterised by white matter
changes, lacunar infarcts and disturbed cerebral autoreg-
ulation, so predisposing them to additional cerebral in-
jury. Moreover, neurological problems in AKI may not
only be directly related to uraemic toxin accumulation,
but may also develop due to electrolyte imbalance, drug
toxicity, thiamine deficiency, and also additionally the
effects of renal replacement therapy, including dialysis
disequilibrium [4]. Encephalopathy may also occur in
the setting of sepsis, as sepsis is not only the commonest
precipitating factor for hospital-acquired AKI but is also
more likely to develop in patients with AKI. Because
AKI is an inflammatory condition, platelet activation
and increased thrombin generation increase the risk of
cerebral ischaemia due to cerebral capillary thrombosis
typically found in cases of malaria-induced and
leptospirosis-induced AKI. In addition, as drug pharma-
cokinetics may be altered in AKI, the risk of drug-
induced encephalopathy is increased.
On the other hand, acute brain injury can lead to neu-
creasing renal sympathetic nervous system activity, so
altering renal blood flow and glomerular filtration, and
by altering vasopressin release lead to changes in sodium
and water balance. In addition, acute brain injury is also a
cause of cerebral salt wasting, and also severe brain injury
leading to brain death results in haemodynamic instability,
hormonal disturbance and increased immunologic re-
sponse, triggering an inflammatory cascade in several or-
gans, including the kidney. Clinically, studies have
reported a link between brain death and increased inflam-
matory response in the kidneys used for organ donation,
leading to donor graft dysfunction [5,6]. Similarly, renal
dysfunction in the setting of both acute ischaemic and
haemorrhagic stroke is associated with increased hospital
stay and mortality [7].
Although there is overlap between encephalopathy in
patients with AKI and those with end-stage chronic kid-
ney disease (CKD), this review will concentrate mainly
on the effects of AKI on the brain, and conversely the ef-
fects of acute brain injury on the kidney, rather thantral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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the insults that affect the brain and kidney.
Acute kidney injury and the brain
Injury in one organ can lead to changes in a distant organ,
and vice versa. The interactions between the liver and the
kidney [8] and between the heart and the kidney are the
best categorised and often referred to as the hepato-renal
syndrome and the cardio-renal syndromes [9]. The kidney
not only plays a key role in maintaining electrolyte, acid–
base, sodium and water homeostasis, but also in metabolis-
ing hormones and excreting toxins. As such, AKI is likely
to challenge cerebral homeostasis both at the cellular level
[10] and also by altering neurotransmitter concentrations,
circulating cytokines, acid–base imbalance, haemostasis,
and drug metabolism (Table 1 and Figures 1 and 2).
These potentially pathophysiological changes contribute
to both direct and indirect insults to the brain. For ex-
ample, there is an increased risk of both cerebral haemor-
rhage and thrombosis with AKI due to the combination of
endothelial injury, abnormal platelet function and coagula-
tion cascade dysregulation – particularly associated with
cerebral involvement with Dengue fever and other haemor-
rhagic viral infections, leptospirosis and both thrombotic
thrombocytopenic purpura and haemolytic uraemic syn-
drome [4]. Furthermore, in the setting of AKI secondary to
Goodpasture’s syndrome or systemic vasculitides patients
may develop steroid-induced psychosis, on the one hand,
and the risk of overimmunosuppression in the immuno-
compromised patient, on the other, including AKI in
the renal transplant recipient increasing the risk of enceph-
alopathy due to primary brain infections with bacterial,
viral, fungal or atypical organisms. In addition, monoclonal
and polyclonal antibodies to lymphocytes may precipitate a
sudden cytokine release resulting in encephalopathy or
aseptic meningitis, and excess immunophyllin dosing may
also cause an encephalopathy associated with characteristic
cerebral white matter changes.Table 1 Summary of mechanisms associated with cerebral dy
Mechanism Results
Impaired blood–brain barrier integrity Alteration of essential amino acid
the brain
Neurotransmitter derangement Decreased cerebral norepinephri
Trigger inflammatory cascade Three waves of danger signalling
box 1 protein
Acid–base disturbance Activation of acid-sensing ion ch
Local vasodilatory effects as a res
Organic osmolyte and brain water
disturbance
Increased intracellular idiogenic o
Alteration of drug pharmacokinetics Downregulation of organic acid
Alteration of protein binding of d
Impaired renal and hepatic clearBlood–brain barrier integrity and disruption in
acute kidney injury
The blood–brain barrier (BBB) and the blood–cerebro-
spinal fluid barrier (BCSFB) are designed to maintain
cerebral homeostasis. These structures play a major role
in regulating the transport of amino acids, proteins, and
essential nutrients into and out of the brain. The integ-
rity of the BBB and the BCSFB depends on the mainten-
ance of tight junctions between cerebral endothelial cells
and the choroid plexus, supported by astrocytes, which
are specialised glial cells. Disruption of the BBB and the
BCSFB can allow the influx of proteins, amino acids and
inflammatory cells into the brain tissue.
The effects of AKI on BBB permeability are not well
characterised. However, there are numerous studies
reporting disruption of BBB integrity in various inflam-
matory models including sepsis [11,12], liver failure
[13,14], and neurological disease [15,16]. AKI is recog-
nised to lead to systemic inflammation, due to the in-
flammatory response within the kidney [17,18], so AKI
may similarly share the common inflammatory pathways
that increase endothelial permeability [12] and BBB per-
meability. AKI increases proinflammatory cytokine gen-
eration, but also reduces cytokine clearance – so
increasing the overall inflammatory response [19,20],
leading to leukocyte activation and recruitment, activa-
tion of the complement cascade pathway, and amplifying
the humoral immune response [21]. A sudden reduction
in kidney function leads to toxin accumulation and in-
creased serum osmolality, which can directly stimulate
vascular endothelial growth factor [22] as well as in-
creasing reactive oxygen species, resulting in endothelial
injury [22,23], BBB disruption, upregulation of toll-like
receptors [24], neuronal activating protein [10,25] and
brain transporters (Figure 1).
Animal models of AKI have demonstrated disruption
of the BBB with extravasation of albumin-bound Evans
blue dye compared with sham-operated controls [12,25].sfunction during acute kidney injury
concentrations, inflammatory mediators and organic osmolyte in
ne, epinephrine and dopamine may lead to impaired locomotor activity
unleashing uric acid, Weibel–Palade bodies and high mobility group
annels leading to cellular injury
ult of cerebral oedema
smoles and brain water
transporters and organic cation transporters
rug
ance of drug
Figure 1 Schematic diagram depicting the effect of acute kidney injury on integrity of the blood–brain barrier. IS, indoxyl sulphate; OAT,
organic anion transporter; OCT, organic cation transporter; PAH, para-aminohippuric acid; ROS, reactive oxygen species; VEGF, vascular endothelial
growth factor.
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factor alpha or generalised sepsis cause activation of brain
astrocytes, resulting in changes to the BBB, and increased
permeability. These animal studies support the concept
that inflammation associated with AKI with increased cir-
culating cytokines leads to disruption of the BBB, allowing
increased access to inflammatory cells, cytokines, comple-
ment, amino acids and organic osmolytes.Figure 2 Schematic cartoon showing potential pathways of brain and
volume increase.Changes in cerebral neurotransmitters in acute
kidney injury
Complex brain function is tightly controlled by multiple
interneuronal synapses using combinations of excitatory
and inhibitory neurotransmitters. Derangements in the
metabolism of these neurotransmitters may variably dis-
rupt cerebral function, ranging from coma to hyperexci-
tation states. Interactions between the kidney and thekidney crosstalk. OAT, organic anion transporter; RVI, regulatory
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have been well described in animal models for more
than three decades [10,26].
Transport across the BBB is normally highly regulated.
Most animal studies in AKI have centred on amino acid
transport; for example, the Na+-independent cationic
amino acid transporter 1 (CAT1/SLC7A1), which regu-
lates L-arginine influx into the brain [27]. As L-arginine is
the precursor for guanidine compounds, including tau-
rine, alanine, glycine, guanidinoacetic acid and creatine,
any interference with this transporter during AKI may
both potentially cause the accumulation of and also the
depletion of amino acids and neurotransmitters within the
brain. Some amino acids are strictly regulated to have very
low concentrations in brain tissue by active efflux into the
circulation via a series of transporters. Glutamate, aspartic
acid, glycine, gamma aminobutyric acid, and taurine are
actively exported out through excitatory amino acid trans-
porters, so disruption of these transporters due to changesTable 2 Summary of animal studies of different models of acu
Study Subjects Model
Ali and colleagues [26] Rats Nephrectomy
Jeppsson and colleagues [30] Rats IRI
Adachi and colleagues [29] Rats IRI





Fuquay and colleagues [21] Mice IRI
Liu and colleagues [25] Mice Nephrectomy, IRI
Trachtman and colleagues [45] Rats Urethral ligation
Silver [47] Rats Urethral ligation
Galons and colleagues [48] Rats Nephrectomy
AKI, acute kidney injury; IRI, ischaemic reperfusion injury.in BBB integrity in AKI can lead to accumulation within
the brain.
Brain catecholamine concentrations are often depleted
in animal models of AKI [28]. Changes in catecholamine
neurotransmitter metabolism have been associated with
impaired motor activity [29], which is supported by ex-
perimental studies reporting a fall in plasma valine and
threonine but increased brain phenylalanine, tyrosine, and
histidine [30], so potentially increasing the amount of
cerebral monoamine neurotransmitters, with alteration of
mental status and motor disability [31] (Table 2).
How important these changes in neurotransmitters are
in causing the alteration of cerebral function often wit-
nessed in clinical practice is unknown, although the in-
creased risk of developing delirium in the intensive care
setting associated with the use of gamma aminobutyric
acidA agonists and anticholinergic drugs suggests that al-
terations in these neurotransmitters play a contributory
role [32].te kidney injury reporting effects on the brain
Findings
Increased plasma norepinephrine, epinephrine and dopamine
Decreased cerebral norepinephrine, epinephrine and dopamine
Reduced plasma valine and threonine but increased plasma
phenylalanine
Increased phenylalanine, tyrosine, and histidine, but decreased
threonine in the brain
Unchanged in cerebral norepinephrine and serotonin turnover as well
as brain water content
Decrease in cerebral dopamine metabolism and motor activity
Moderate increase in neuronal activation in the biogenic amine
expressing cell group
Strongly increased neuronal activation in stress-sensitive brain nuclei
and central regulation of salt and water balance area
Variable increase in neuronal activation in central autonomic cell group
Increased cytokine production and decreased renal clearance
Magnified humoral immune response
Increase of proinflammatory chemokines (keratinocyte-derived
chemoattractant, monocyte chemoattractant protein-1, macrophage
inflammatory protein) in the kidney
Elevation of keratinocyte-derived chemoattractant, granulocyte
colony-stimulating factor and glial fibrillary acidic protein in the brain
No change in brain water content
Increased blood–brain barrier permeability (extravasation of Evan blue
dye in the brain)
Decreased brain water at 8 hours and increased organic osmolyte in
the brain at 48 hours
No significant change in brain organic osmolyte
Decrease in brain water content
No difference in brain water content
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injury
Peptide hormones are freely filtered by the glomerulus
and are then taken up by the proximal tubule, degraded
and recycled as amino acids. However, most laboratories
measure total hormone levels, a combination of free and
protein-bound hormone, and some assays will measure
both active hormone but also precursor and inactive hor-
mones. As such, interpretation of hormone profiles in
AKI has been difficult to disentangle. However, free T3
levels tend to fall in AKI, whereas catecholamines, vaso-
pressin, natriuretic peptides and the renin–angiotensin–
aldosterone axis increase. Renal sympathetic nervous sys-
tem overactivity has been reported to increase the risk of
hypertension and the development of the posterior revers-
ible encephalopathy syndrome due to ischaemic injury
and oedema in the medulla and cerebellum [33].
Effect of inflammatory changes induced by acute
kidney injury on the brain
Although the BBB regulates endothelial permeability, one
should also remember that the endothelium-lining capil-
laries in the median eminence at the base of the third ven-
tricle are fenestrated and as such will allow increased
passage of cytokines and other inflammatory mediators
into this area of the brain. Increasing circulating inflam-
matory cytokines (IL-1B, IL-8 and tumour necrosis factor
alpha) in a rat model altered mRNA transcription proteins
for nuclear factor-κB, cyclooxygenase-2, CCL2, CXCL1,
IL-1B, and tumour necrosis factor alpha in the hypothal-
amic and hippocampus [34]. Furthermore, these changes
were shown to lead to altered brain function, including
decreased locomotor activity in a mouse model of AKI
[25].
Interestingly, although this AKI model resulted in a
significant increase in the generalised systemic inflamma-
tory response with increased serum C-reactive protein,
granulocyte colony-stimulating factor, IL-1B, IL-6 and
keratinocyte-derived chemoattractant, there were signifi-
cant differences in the inflammatory reaction within dif-
ferent organs, with increased macrophage inflammatory
protein and monocyte chemoattractant protein-1 in the
kidney, whereas in the cerebral cortex and corpus collo-
sum of the brain there were substantial increases for
keratinocyte-derived chemoattractant and granulocyte
colony-stimulating factor, as well as glial fibrillary acidic
protein, a specific cellular marker of brain inflammation
[25] (Table 2). Importantly, glial fibrillary acidic protein
did not increase in corresponding animal models of acute
liver injury, suggesting that this effect was relatively spe-
cific for AKI and not just simply associated with general-
ised inflammation following other acute organ injury.
More recently, Ratliff and colleagues simplified the
systemic inflammatory response in AKI in three wavesof danger signalling, starting within minutes after renal
ischaemia [18]. The first danger signal is associated with
a surge in uric acid, a marker and mediator of renal is-
chaemic injury, triggering a secondary response, charac-
terised by the exocytosis of Weibel–Palade bodies,
releasing their proinflammatory mediators including
endothelin-1, large multimers of von Willebrand factor,
IL-8 and angiopoietin-2. Direct activation of the innate
immune system via Toll-like receptors, as a result of the
release of high mobility group box 1 protein and DNA
binding protein, which act as potent cytokine-like medi-
ators in the systemic circulation, leads to an intense in-
flammatory response within hours of ischaemic renal
injury [18].
Synthesising the results of these studies, the inflamma-
tory response observed in AKI leads to disruption of
the BBB, endothelial injury and stimulation of the in-
flammatory and coagulation cascades within the brain
via inflammatory cell responses leading to changes in
neuronal cell protein transcription and cellular activa-
tion, altering cerebral function.
Acid–base disturbances
The kidney plays a key role in acid–base balance regula-
tion, to allow optimal cellular metabolism and function.
AKI by predisposing to metabolic acidosis may play a
detrimental role affecting cerebral neuronal metabolism
and may impair normal cerebral function. One of the im-
portant enzyme systems in human cell metabolism is glu-
tamate dehydrogenase, which uses ammonia, NADP(H)
and NAD(H) to reversibly convert alpha-ketoglutarate to
glutamate. Changes in acid–base balance might affect the
affinity of protons for intermediary intracellular metabol-
ism by altering energy generation. Increasing intracellular
acidification leads to an increasing affinity of ammonia Km
[NH4+] for human glutamate dehydrogenase, so resulting
in oxidative deamination of glutamate [35], and thus
altering neurotransmitter balance, with excess ammonia
cycling between neurons and astrocytes [36].
In addition, in an increasingly intracellular acidic en-
vironment, protons can activate acid-sensing ion chan-
nels – resulting in an influx of both sodium and calcium
into the cell, leading to cell membrane depolarisation
and cellular injury and cell death [37,38]. Decreasing
intracellular pH can induce calcium influx in an acid-
sensing ion channels knockout cell model via voltage-
gated calcium channels, resulting in an alteration of
neural cell plasticity and increased cell injury [39].
Furthermore, the reduction in pH in the cerebrospinal
fluid has local vasodilatory effects on the cerebral paren-
chymal arterioles through activation of large conductant,
calcium-sensitive potassium channels [40], due to a
combination of declining calcium wave activity and a
significant elevation of calcium spark activity in the
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with increased risk of localised cerebral oedema.
Metabolic acidosis also has other effects, including
changing free concentrations to bound concentrations of
calcium and magnesium, which impact on cellular ion
fluxes, electrical gradients and neurotransmission, and
also the protein binding of both azotaemic toxins and
drugs that could affect their therapeutic effectiveness
and also could result in accumulation and neurotoxicity
[41].
Organic osmolytes and brain water changes in
acute kidney injury
AKI results in the retention of the waste products of ni-
trogen metabolism, typified by urea accumulation. In-
creased plasma urea leads to increased astrocyte and
neuronal urea concentrations. Increasing intracellular
urea risks intracellular hypertonicity and cell swelling in
CKD. This outcome can be made worse by intracellular
acidosis, which increases idiogenic osmoles. Diuretics
may potentially exacerbate these effects by both redu-
cing the effective plasma volume and cerebral perfusion,
and also by causing electrolyte abnormalities [42]. Loop
diuretics have been recently shown to alter aquaporin
channel expression, so altering the passage of water
through cells.
As the intracellular osmolality increases, glial cells and
neurons initially compensate by excreting sodium, potas-
sium and calcium and other osmotically active organic
anions. However, depending upon the rate of urea pro-
duction and when complicated by intracellular acidosis,
the cellular compensatory mechanisms may become
exhausted and glial cell and neuronal swelling occurs,
with disruption of normal cellular metabolism, leading
to uraemic encephalopathy described in CKD [43],
which can produce a wide range of clinical manifesta-
tions from drowsiness to stupor, coma and even general-
ised seizures. In AKI, however, the time course of
increasing serum urea and other azotaemic toxins is
more rapid [44], and compensatory defence mechanisms
take time to become fully operational. As such, the clas-
sic study of AKI in a rat model showed an accumulation
of organic osmolytes in the brain tissues of rats within
48 hours of developing AKI, which was proceeded by a
reduction of brain water at 8 hours [45]. This initial re-
sponse is well recognised as a regulatory volume in-
crease, with the brain transiently generating idiogenic
osmoles derived from amino acids such as glutamine,
taurine and inositol to equalise the osmolality gradient
of hyperosmolal state in uraemia [46]. However, these
findings have not been repeated by all investigators.
For example, Silver did not find any difference in
organic osmolytes, myoinositol, taurine, glutamate, glu-
tamine, aspartate, alanine and glycine between uraemicnondialysed mice and nonuraemic controls using a
mouse model, although significant decreases in brain
water, measured by weight, were also observed in ur-
aemic nondialysed mice when compared with normal
control animals at 42 hours [47]. Other studies using dif-
ferent animal models failed to show any significant dif-
ference in the amount of brain water in nephrectomised
nondialysed mice compared with normal control animals
[25,48], and similarly for rat models of ischaemic AKI
[29].
Unfortunately there are no comparative human studies
in AKI; although Chen and colleagues showed signifi-
cantly increased brain water measured by diffusion-
weighted magnetic resonance imaging compared with
normal controls [49], this study was performed in CKD
patients, and as such the changes reported during
chronic dialysis [50] may not be representative of those
in AKI.
Although there are contradictory data between animal
models in the accumulation of organic osmolytes and
brain water, a regulatory brain volume increase would be
expected to equalise the hyperosmolarity associated with
AKI.
Effect of acute kidney injury on organic ion
transporters and drug metabolism
Organic anions and cations are excreted by the kidney
by glomerular filtration and tubular secretion. Tubular
secretion plays a major role in the excretion of not only
organic acids but also exogenous chemical compounds.
Organic anion transporters (OATs) are substrate specific
for endogenous and exogenous anions [51]. OAT4 is
located on the apical cell membrane for transporting
anionic substrates from the luminal area into blood,
whereas OAT1 to OAT3 are located on the basolateral
membrane. Contrastingly, the organic cation trans-
porters OCT1 to OCT3 are located on the basolateral
membrane for transporting cationic compounds between
the proximal tubules and blood. Some of these trans-
porters are also found in the brain, with OCT3 and
OAT3 expressed in the BBB and the BCSFB, modulating
the efflux of organic solutes across the brain [52,53].
Indoxyl sulphate is an anionic and albumin-bound
uremic toxin, and hence glomerular filtration is consid-
ered a minor process for excretion and tubular secretion
is responsible for major excretion [54]. In rat models of
CKD, OAT1 and OAT3 play a major role in transcellular
transport for indoxyl sulphate [55] similar to humans
[56]. Moreover, Schneider and colleagues reported de-
creased para-aminohippurate clearance, another protein-
bound uraemic toxin, in an animal model of AKI associ-
ated with reduced mRNA expression for OAT1 and
OAT3 [57], suggesting that OAT1 and OAT3 play a
major role in uraemic toxin excretion in AKI. In uraemic
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a major role in reducing the efflux of drugs and organic
solutes from the brain, which is exacerbated by competi-
tive solute competition for the transporters [58,59].
Many sedatives, opioid analgesics and other drugs with
central nervous actions have either significant parent
drug or metabolite renal clearance, and as such have al-
tered metabolism in AKI, with increased half-lives
resulting in potential drug accumulation [59]. As such,
the patient with AKI is at greater risk of developing
a confused state. In addition, decreased OAT1 and
OAT3 activity decreases methotrexate, nonsteroidal
anti-inflammatory drug and acetylsalicylic acid elimin-
ation in AKI. Penicillin antibiotics compete for OAT
transport, and thus patients with AKI are more at risk of
developing penicillin-associated encephalopathy due to
drug accumulation and increased brain concentrations.
In addition to OATs, another family of cell membrane
transporters – the ATP-dependent P-glycoprotein trans-
porters – is also important in increasing drug clearance
and is downregulated in AKI, potentially decreasing drug
clearance and increasing drug exposure [60].
In addition, AKI not only reduces renal drug clearance
but may also impair hepatic clearance by altering drug
binding, on the one hand reducing protein binding of
theophylline, phenytoin and methotrexate and on the
other increasing protein binding of propranolol, cimeti-
dine and clonidine [41]. Altering drug pharmacokinetics
affecting the concentration of active metabolites may
lead to drug accumulation and toxicity – for example,
acyclovir and tacrolimus-induced encephalopathy – un-
less drug dosages are appropriately modified for renal
function.
Effect of acute brain injury on the kidney
Acute cerebral injury can lead to acute changes in renal
sodium handling due both to changes in vasopressin se-
cretion and to cerebral sodium wasting. Both excess anti-




Urine sodium concentration Normal or ↑
Plasma renin ± ↑
Plasma aldosterone ↑
Serum urate ↓↓
Fractional excretion urate ↑↑
Fractional excretion phosphate ± ↑
↓, decreased; ↑, increased; ↓↓, greatly decreased; ↑↑, greatly increased.antidiuretic hormone secretion) and cerebral sodium
wasting may occur post acute subarachnoid haemorrhage
and pituitary surgery, and although both cause hypona-
traemia, clinical examination should establish that patients
with syndrome of inappropriate antidiuretic hormone se-
cretion are euvolaemic or hypervolaemic, whereas patients
with cerebral salt wasting are typically hypovolaemic
(Table 3) [61].
Acute cerebral injury is often associated with increased
visceral sympathetic nervous system activity and plasma
catecholamines resulting in systolic hypertension. Al-
though this may be a compensatory mechanism to pre-
serve perfusion to areas of damaged brain, increased
visceral sympathetic nervous system activation results in
reduced renal glomerular perfusion with increased renal
sodium reabsorption. Sustained severe hypertension may
lead to red cell fragmentation, haemolysis and AKI sec-
ondary to red cell thrombi in the glomeruli, similar to
that found with thrombotic thrombocytopenic purpura.
Acute irreversible brain injury
The increasing use of cadaveric kidneys from brain-dead
donors has led to research into the effects of brain death
on renal function. Sanchez-Fructuoso and colleagues re-
ported that the renal allograft survival rate from de-
ceased donors was significantly lower than that for living
related donors [62]. Furthermore, other studies reported
that donor brain death was correlated with both delayed
allograft function and increased acute rejection [63].
Brain death may affect the kidney by a combination of
haemodynamic effects [64], neurohormonal activation
[65], inflammatory response [66] and endothelial activa-
tion [67]. Most of the recent studies have concentrated
on the inflammatory response in the allograft, with re-
ports of both increased upregulation of kidney injury
molecule-1 and inflammatory cytokines including IL-8
and IL-10, but also increased numbers of trafficking in-
flammatory cells such as FoxP3+ regulatory T cells [68],
leading to reduce allograft survival [5].wasting and syndrome of inappropriate antidiuretic
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patients with traumatic brain injury, secondary to
subarachnoid haemorrhage and post cardiac
arrest
The majority of patients with acute traumatic brain in-
jury are young and have normal pre-existing renal func-
tion, but even so the reported incidence of AKI stage 1
has been reported to be around 23%, with only a small
minority requiring renal replacement therapy. However,
the mortality in some studies increased fivefold for pa-
tients with AKI [69]. In other studies, greater use of
mannitol was associated with an increased incidence of
AKI, and intracranial pressure monitoring may reduce
the risk of AKI by reducing mannitol usage [70].
Although patients with acute subarachnoid haemor-
rhage are usually older with a past history of hyperten-
sion, the incidence of AKI has also been reported to be
around 23%, but with a twofold increase in worse func-
tional recoveries and the mortality increasing with sever-
ity of AKI class [71]. Somewhat surprisingly, as patients
suffering cardiac arrest may be expected to have some
underlying degree of pre-existing cardiac and vascular
disease, the rates of AKI reported have been lower –
18% AKI stage 1 and 10% AKI stage 3 – with no re-
ported excess mortality with AKI [72].Management of acute kidney injury in the patient
with acute brain injury
The majority of patients with acute traumatic brain in-
jury are young and have normal renal function. However,
they may be at risk of AKI secondary to blood loss from
multiple trauma, exposure to radiocontrast agents and
prescription of nephrotoxic antibiotics to treat sepsis
and nonsteroidals for analgesia. On the other hand, pa-
tients admitted with subarachnoid haemorrhage and
acute stroke are usually older and more likely to have a
background of CKD secondary to hypertension and
small vessel disease associated with diabetes and cardio-
vascular disease. As such, maintaining adequate hydra-
tion is an important clinical goal for preventing AKI,
particularly for reducing the risk of contrast-induced ne-
phropathy. In addition, multiple contrast exposure
should be minimised by selecting other imaging tech-
niques wherever possible, and nephrotoxic drugs should
be similarly avoided if possible.Renal replacement therapy for acute kidney injury
in patients with acute brain injury
Although renal replacement therapy can help improve
encephalopathy due to uraemia, by removing azotaemic
retention products and reducing toxic drug levels, too
rapid a fall in serum urea may paradoxically cause cere-
bral oedema.Intermittent haemodialysis using modern-day high-
efficiency dialysers coupled with dialysates containing
supraphysiological levels of bicarbonate can exacerbate
underlying brain damage. Urea is rapidly removed from
the plasma water during intermittent haemodialysis, but
there is a delay in urea moving out of cells, including
neurons and cerebrospinal fluid [73]. This leads to the
development of a concentration gradient, and – as water
movement through aquaporins is some 20 times faster
than urea transport – water will move along the concen-
tration gradient generated by the difference in urea con-
centrations, passing into the brain, leading to brain
swelling [74]. Similarly the current practice, particularly
in the United States, of choosing dialysate bicarbonate
concentrations ≥38 mmol/l poses a problem, because
under normal conditions cerebrospinal pH is a little
lower than that of blood, and brain intracellular pH
lower still. The rapid increase in blood pH during dialy-
sis sets up a disequilibrium; as bicarbonate is charged it
only slowly crosses into cells, whereas the reaction be-
tween bicarbonate and hydrogen ions in plasma water
leads to carbon dioxide, which rapidly transverses lipid-
rich cell membranes and once inside cells generates
hydrogen ions, generating a paradoxical intracellular
acidosis, which itself leads to generation of intracellular
idiogenic osmoles, so increasing osmolality further and
increasing water entry. In addition, these changes in
cerebral pH adversely affect the respiratory centre in
those patients spontaneously breathing, increasing the
risk and frequency of apneic spells. As such, continuous
forms of renal replacement therapy are to be preferred
so that the rate of change in serum urea and bicarbonate
are slower, and risk of brain swelling is reduced [75,76].
It is equally important to avoid intradialytic hypotension
to minimise iatrogenic episodes of cerebral ischaemia [77].
The risk of cardiovascular stability during dialysis can be
reduced by cooling the dialysate to 35°C, and increasing
the dialysate sodium to around 10 mEq/l above serum so-
dium [78]. As such, slowing down the intermittent
haemodialysis session by moving towards prolonged inter-
mittent renal replacement therapy, with slower blood and
dialysate flows coupled with high dialysate sodium and
cooling, as can be achieved with the Genius® (Fresenius
AG, BadHomburg, Germany) dialysis system, may prove
equally as effective as continuous renal replacement ther-
apy in preventing an increase in cerebral oedema. How-
ever, prolonged intermittent renal replacement therapy
using a combination of higher blood flows, warmed and
lower sodium hypotonic dialysates risks an increase in
intracranial pressure [79,80]. Peritoneal dialysis is a con-
tinuous renal replacement therapy and, although associ-
ated with slower solute clearances than haemodialysis, can
also lead to an increase in brain swelling in brain-injured
patients, as all commercial dialysates are hyponatraemic
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cose content. Also, instillation and drainage of hypertonic
glucose dialysates can lead to swings in right atrial filling,
with a consequent reduction in cardiac output that may
compromise cerebral perfusion [76,81].
Conclusion
Cerebral dysfunction is a common finding in patients
with AKI. Although alterations of mental status are
more likely to occur in the older patient with pre-
existing small vessel cerebrovascular disease, sepsis is
probably the most common triggering factor. However,
AKI is an inflammatory state per se, affecting distant
organ injury mediated by increased circulating cytokines
and other inflammatory mediators, due to a combination
of increased production and reduced clearance. In-
creased circulating cytokines and other inflammatory
mediators predispose to alterations in the BBB, leading
to increased permeability and changes in neuronal
homeostasis. This is exacerbated by changes in excita-
tory and inhibitory neurotransmitter concentrations.
AKI leads to the retention of azotaemic products of ni-
trogen metabolism and metabolic acidosis, which lead to
changes in intracellular osmolality and further disturb
intracellular homeostasis. Alterations in drug pharmaco-
kinetics in patients with AKI may then lead to parent
drug or metabolite accumulation, which may further
alter higher mental functions and increase the risk for
cerebral dysregulation.
Patients admitted with acute cerebral dysfunction are
at risk of AKI primarily secondary to hypovolaemia, re-
duced intrarenal glomerular perfusion, and exposure to
radiocontrast and nephrotoxic drugs. As such, achieving
adequate hydration and avoiding or minimising nephro-
toxin exposure is key to preventing AKI. For patients
who develop progressive AKI requiring renal replace-
ment therapy, modifying the dialysis prescription may
minimise further brain injury. These modifications
would include continuous renal replacement therapy or
intermittent haemodialysis with reduced blood flow rate,
a longer daily dialysis session time in combination with
smaller surface area biocompatible dialysers, and cooled
dialysate with increased sodium and reduced bicarbonate
dialysate concentrations.
Abbreviations
AKI: Acute kidney injury; BBB: Blood–brain barrier; BCSFB: Blood–
cerebrospinal fluid barrier; CKD: Chronic kidney disease; IL: Interleukin;
OAT: Organic anion transporter; OCT: Organic cation transporter.
Competing interests
The authors declare that they have no competing interests.
Author details
1Renal Unit, Department of Medicine, Faculty of Medicine, Ramathibodi
Hospital, Mahidol University, 34/1 Soi Saengsuksa School, Isarapap Road, Min
Buri, Bangkok 10510, Thailand. 2UCL Centre for Nephrology, Royal FreeHospital, University College London Medical School, Rowland Hill Street,
London NW3 2PF, UK. 3Bumrungrad International Hospital, 33 Sukhumvit Soi
3, Wattana, Bangkok 10110, Thailand.
Published: 5 June 2014
References
1. Li X, Hassoun HT, Santora R, Rabb H: Organ crosstalk: the role of the
kidney. Curr Opin Crit Care 2009, 15:481–487.
2. Yap SC, Lee HT: Acute kidney injury and extrarenal organ dysfunction:
new concepts and experimental evidence. Anesthesiology 2012,
116:1139–1148.
3. Grams ME, Rabb H: The distant organ effects of acute kidney injury.
Kidney Int 2012, 81:942–948.
4. Brouns R, De Deyn PP: Neurological complications in renal failure: a
review. Clin Neurol Neurosurg 2004, 107:1–16.
5. Floerchinger B, Oberhuber R, Tullius SG: Effects of brain death on organ
quality and transplant outcome. Transplant Rev (Orlando) 2012, 26:54–59.
6. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S: High survival rates of
kidney transplants from spousal and living unrelated donors. N Engl J
Med 1995, 333:333–336.
7. Khatri M, Himmelfarb J, Adams D, Becker K, Longstreth WT, Tirschwell DL:
Acute kidney injury is associated with increased hospital mortality after
stroke. J Stroke Cerebrovasc Dis 2014, 23:25–30.
8. Davenport A: AKI in a patient with cirrhosis and ascites. Clin J Am Soc
Nephrol 2012, 7:2041–2048.
9. Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM,
Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M,
Hillege H, House A, Katz NM, Maisel A, Mankad S, Zanco P, Mebazaa A,
Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N,
Ponikowski P: Epidemiology of cardio-renal syndromes: workgroup
statements from the 7th ADQI Consensus Conference. Nephrol Dial
Transplant 2010, 25:1406–1416.
10. Palkovits M, Sebekova K, Gallatz K, Boor P, Sebekova K Jr, Klassen A, Bahner
U, Heidland A: Neuronal activation in the CNS during different forms of
acute renal failure in rats. Neuroscience 2009, 159:862–882.
11. Yokoo H, Chiba S, Tomita K, Takashina M, Sagara H, Yagisita S, Takano Y,
Hattori Y: Neurodegenerative evidence in mice brains with cecal ligation
and puncture-induced sepsis: preventive effect of the free radical
scavenger edaravone. PLoS One 2012, 7:e51539.
12. Tsao N, Hsu HP, Wu CM, Liu CC, Lei HY: Tumour necrosis factor-alpha
causes an increase in blood–brain barrier permeability during sepsis.
J Med Microbiol 2001, 50:812–821.
13. Chastre A, Belanger M, Nguyen BN, Butterworth RF: Lipopolysaccharide
precipitates hepatic encephalopathy and increases blood–brain barrier
permeability in mice with acute liver failure. Liver Int 2013.
doi:10.1111/liv.12252.
14. Butterworth RF: The liver–brain axis in liver failure: neuroinflammation
and encephalopathy. Nat Rev Gastroenterol Hepatol 2013, 10:522–528.
15. Johnson HL, Jin F, Pirko I, Johnson AJ: Theiler’s murine encephalomyelitis
virus as an experimental model system to study the mechanism of
blood–brain barrier disruption. J Neurovirol 2014, 20:107–112.
16. Lakhan SE, Kirchgessner A, Tepper D, Leonard A: Matrix metalloproteinases
and blood–brain barrier disruption in acute ischemic stroke. Front Neurol
2013, 4:32.
17. Kinsey GR, Li L, Okusa MD: Inflammation in acute kidney injury. Nephron
Exp Nephrol 2008, 109:e102–e107.
18. Ratliff BB, Rabadi MM, Vasko R, Yasuda K, Goligorsky MS: Messengers
without borders: mediators of systemic inflammatory response in AKI.
J Am Soc Nephrol 2013, 24:529–536.
19. Andres-Hernando A, Dursun B, Altmann C, Ahuja N, He Z, Bhargava R,
Edelstein CE, Jani A, Hoke TS, Klein C, Faubel S: Cytokine production
increases and cytokine clearance decreases in mice with bilateral
nephrectomy. Nephrol Dial Transplant 2012, 27:4339–4347.
20. Chen J, John R, Richardson JA, Shelton JM, Zhou XJ, Wang Y, Wu QQ,
Hartono JR, Winterberg PD, Lu CY: Early interleukin 6 production by
leukocytes during ischemic acute kidney injury is regulated by TLR4.
Kidney Int 2011, 80:504–515.
21. Fuquay R, Renner B, Kulik L, McCullough JW, Amura C, Strassheim D,
Pelanda R, Torres R, Thurman JM: Renal ischemia–reperfusion injury
Nongnuch et al. Critical Care 2014, 18:225 Page 10 of 11
http://ccforum.com/content/18/3/225amplifies the humoral immune response. J Am Soc Nephrol 2013,
24:1063–1072.
22. Chi OZ, Hunter C, Liu X, Tan T, Weiss HR: Effects of VEGF on the
blood–brain barrier disruption caused by hyperosmolarity. Pharmacology
2008, 82:187–192.
23. Sadik NA, Mohamed WA, Ahmed MI: The association of receptor of
advanced glycated end products and inflammatory mediators
contributes to endothelial dysfunction in a prospective study of acute
kidney injury patients with sepsis. Mol Cell Biochem 2012, 359:73–81.
24. Salama M, Farrag SM, Abulasrar SA, Amin MM, Ali AA, Sheashaa H, Sobh M,
Arias-Carrión O: Up-regulation of TLR-4 in the brain after ischemic
kidney-induced encephalopathy in the rat. CNS Neurol Disord Drug Targets
2013, 12:583–586.
25. Liu M, Liang Y, Chigurupati S, Lathia JD, Pletnikov M, Sun Z, Crow M, Ross
CA, Mattson MP, Rabb H: Acute kidney injury leads to inflammation and
functional changes in the brain. J Am Soc Nephrol 2008, 19:1360–1370.
26. Ali F, Tayeb O, Attallah A: Plasma and brain catecholamines in
experimental uremia: acute and chronic studies. Life Sci 1985,
37:1757–1764.
27. O’Kane RL, Vina JR, Simpson I, Zaragoza R, Mokashi A, Hawkins RA: Cationic
amino acid transport across the blood–brain barrier is mediated
exclusively by system y+. Am J Physiol Endocrinol Metab 2006,
291:E412–E419.
28. Haase-Fielitz A, Haase M, Bellomo R, Lambert G, Matalanis G, Story D,
Doolan L, Buxton B, Gutteridge G, Luft FC, Schunck WH, Dragun D:
Decreased catecholamine degradation associates with shock and kidney
injury after cardiac surgery. J Am Soc Nephrol 2009, 20:1393–1403.
29. Adachi N, Lei B, Deshpande G, Seyfried FJ, Shimizu I, Nagaro T, Arai T:
Uraemia suppresses central dopaminergic metabolism and impairs
motor activity in rats. Intensive Care Med 2001, 27:1655–1660.
30. Jeppsson B, Freund HR, Gimmon Z, James JH, von Meyenfeldt MF, Fischer
JE: Blood–brain barrier derangement in uremic encephalopathy. Surgery
1982, 92:30–35.
31. Daniel PM, Moorhouse SR, Pratt OE: Amino acid precursors of monoamine
neurotransmitters and some factors influencing their supply to the
brain. Psychol Med 1976, 6:277–286.
32. Reade MC, Finfer S: Sedation and delirium in the intensive care unit. N
Engl J Med 2014, 370:444–454.
33. Wei SG, Zhang ZH, Beltz TG, Yu Y, Johnson AK, Felder RB: Subfornical organ
mediates sympathetic and haemodynamic responses to blood-borne
proinflammatory cytokines. Hypertension 2013, 62:118–125.
34. Skelly DT, Hennessy E, Dansereau MA, Cunningham C: A systematic
analysis of the peripheral and CNS effects of systemic LPS, IL-1β, TNF-α
and IL-6 challenges in C57BL/6 mice. PLoS One 2013, 8:e69123.
35. Zaganas I, Pajecka K, Wendel Nielsen C, Schousboe A, Waagepetersen HS,
Plaitakis A: The effect of pH and ADP on ammonia affinity for human
glutamate dehydrogenases. Metab Brain Dis 2013, 28:127–131.
36. Rothman DL, De Feyter HM, Maciejewski PK, Behar KL: Is there in vivo
evidence for amino acid shuttles carrying ammonia from neurons to
astrocytes? Neurochem Res 2012, 37:2597–2612.
37. Zha XM: Acid-sensing ion channels: trafficking and synaptic function.
Mol Brain 2013. doi:10.1186/1756-6606-6-1.
38. Samways DS, Harkins AB, Egan TM: Native and recombinant ASIC1a
receptors conduct negligible Ca2+ entry. Cell Calcium 2009,
45:319–325.
39. Zha XM, Costa V, Harding AM, Reznikov L, Benson CJ, Welsh MJ: ASIC2
subunits target acid-sensing ion channels to the synapse via an
association with PSD-95. J Neurosci 2009, 29:8438–8446.
40. Dabertrand F, Nelson MT, Brayden JE: Acidosis dilates brain parenchymal
arterioles by conversion of calcium waves to sparks to activate BK
channels. Circ Res 2012, 110:285–294.
41. Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S: Drug
protein binding in chronic renal failure: evaluation of nine drugs. Kidney
Int 1988, 33:996–1004.
42. Arampatzis S, Funk GC, Leichtle AB, Fiedler GM, Schwarz C, Zimmermann H,
Exadaktylos AK, Lindner G: Impact of diuretic therapy-associated
electrolyte disorders present on admission to the emergency depart-
ment: a cross-sectional analysis. BMC Med 2013.
doi:10.1186/1741-7015-11-83.
43. Biasioli S, D’Andrea G, Feriani M, Chiaramonte S, Fabris A, Ronco C, La Greca
G: Uremic encephalopathy: an updating. Clin Nephrol 1986, 25:57–63.44. Davenport A, Jones SR, Goel S, Astley JP, Hartog M: Differentiation of acute
from chronic renal impairment by detection of carbamylated
haemoglobin. Lancet 1993, 341:1614–1617.
45. Trachtman H, Futterweit S, Tonidandel W, Gullans SR: The role of organic
osmolytes in the cerebral cell volume regulatory response to acute and
chronic renal failure. J Am Soc Nephrol 1993, 3:1913–1919.
46. Strange K: Regulation of solute and water balance and cell volume in the
central nervous system. J Am Soc Nephrol 1992, 3:12–27.
47. Silver SM: Cerebral edema after rapid dialysis is not caused by an
increase in brain organic osmolytes. J Am Soc Nephrol 1995, 6:1600–1606.
48. Galons JP, Trouard T, Gmitro AF, Lien YH: Hemodialysis increases apparent
diffusion coefficient of brain water in nephrectomized rats measured by
isotropic diffusion-weighted magnetic resonance imaging. J Clin Invest
1996, 98:750–755.
49. Chen CL, Lai PH, Chou KJ, Lee PT, Chung HM, Fang HC: A preliminary
report of brain edema in patients with uremia at first hemodialysis:
evaluation by diffusion-weighted MR imaging. Am J Neuroradiol 2007,
28:68–71.
50. Davenport A: Continuous renal replacement therapies in patients with
acute neurological injury. Semin Dial 2009, 22:165–168.
51. Hosoya K, Tachikawa M: Roles of organic anion/cation transporters at the
blood–brain and blood–cerebrospinal fluid barriers involving uremic
toxins. Clin Exp Nephrol 2011, 15:478–485.
52. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T: Rat
organic anion transporter 3 (rOAT3) is responsible for brain-to-blood
efflux of homovanillic acid at the abluminal membrane of brain capillary
endothelial cells. J Cereb Blood Flow Metab 2003, 23:432–440.
53. Koepsell H, Endou H: The SLC22 drug transporter family. Pflugers Arch
2004, 447:666–676.
54. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark
W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres
A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B,
Stenvinkel P, Tetta C, Wanner C, Zidek W, European Uremic Toxin Work
Group (EUTox): Review on uremic toxins: classification, concentration,
and interindividual variability. Kidney Int 2003, 63:1934–1943.
55. Enomoto A, Takeda M, Tojo A, Sekine T, Cha SH, Khamdang S, Takayama F,
Aoyama I, Nakamura S, Endou H, Niwa T: Role of organic anion
transporters in the tubular transport of indoxyl sulfate and the induction
of its nephrotoxicity. J Am Soc Nephrol 2002, 13:1711–1720.
56. Deguchi T, Ohtsuki S, Otagiri M, Takanaga H, Asaba H, Mori S, Terasaki T:
Major role of organic anion transporter 3 in the transport of indoxyl
sulfate in the kidney. Kidney Int 2002, 61:1760–1768.
57. Schneider R, Sauvant C, Betz B, Otremba M, Fischer D, Holzinger H, Wanner
C, Galle J, Gekle M: Downregulation of organic anion transporters OAT1
and OAT3 correlates with impaired secretion of para-aminohippurate
after ischemic acute renal failure in rats. Am J Physiol Renal Physiol 2007,
292:F1599–F1605.
58. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, Terasaki T:
Role of blood–brain barrier organic anion transporter 3 (OAT3) in the
efflux of indoxyl sulfate, a uremic toxin: its involvement in
neurotransmitter metabolite clearance from the brain. J Neurochem 2002,
83:57–66.
59. Sun H, Frassetto L, Benet LZ: Effects of renal failure on drug transport and
metabolism. Pharmacol Ther 2006, 109:1–11.
60. Vilay AM, Churchwell MD, Mueller BA: Clinical review: drug metabolism
and nonrenal clearance in acute kidney injury. Crit Care 2008, 12:235.
61. Maesaka JK, Imbriano LJ, Ali NM, Ilamathi E: Is it cerebral or renal salt
wasting? Kidney Int 2009, 76:934–938.
62. Sanchez-Fructuoso AI, Prats D, Marques M, Blanco J, Torrente J, Conesa J,
Rio FD, Núñez JR, Barrientos A: Does donor brain death influence acute
vascular rejection in the kidney transplant? Transplantation 2004,
78:142–146.
63. Morrissey PE, Monaco AP: Donation after circulatory death: current
practices, ongoing challenges, and potential improvements.
Transplantation 2014, 97:258–264.
64. Herijgers P, Leunens V, Tjandra-Maga TB, Mubagwa K, Flameng W: Changes
in organ perfusion after brain death in the rat and its relation to
circulating catecholamines. Transplantation 1996, 62:330–335.
65. Novitzky D, Cooper DK, Morrell D, Isaacs S: Change from aerobic to
anaerobic metabolism after brain death, and reversal following
triiodothyronine therapy. Transplantation 1988, 45:32–36.
Nongnuch et al. Critical Care 2014, 18:225 Page 11 of 11
http://ccforum.com/content/18/3/22566. Takada M, Nadeau KC, Hancock WW, Mackenzie HS, Shaw GD, Waaga AM,
Chandraker A, Sayegh MH, Tilney NL: Effects of explosive brain death on
cytokine activation of peripheral organs in the rat. Transplantation 1998,
65:1533–1542.
67. Baan CC, Peeters AM, Demmers MW, Mol WM, Boer K, Samsom JN,
Rowshani AT, Ijzermans JN, Weimar W: FoxP3 T cells and the
pathophysiologic effects of brain death and warm ischemia in donor
kidneys. Clin J Am Soc Nephrol 2012, 7:1481–1489.
68. Morariu AM, Schuurs TA, Leuvenink HG, van Oeveren W, Rakhorst G, Ploeg
RJ: Early events in kidney donation: progression of endothelial activation,
oxidative stress and tubular injury after brain death. Am J Transplant
2008, 8:933–941.
69. Li N, Zhao WG, Zhang WF: Acute kidney injury in patients with severe
traumatic brain injury: implementation of the acute kidney injury
network stage system. Neurocrit Care 2011, 14:377–381.
70. Fang L, You H, Chen B, Xu Z, Gao L, Liu J, Xie Q, Zhou Y, Gu Y, Lin S, Ding F:
Mannitol is an independent risk factor of acute kidney injury after
cerebral trauma: a case–control study. Ren Fail 2010, 32:673–679.
71. Zacharia BE, Ducruet AF, Hickman ZL, Grobelny BT, Fernandez L, Schmidt
JM, Narula R, Ko LN, Cohen ME, Mayer SA, Connolly ES Jr: Renal
dysfunction as an independent predictor of outcome after aneurysmal
subarachnoid haemorrhage: a single-center cohort study. Stroke 2009,
40:2375–2381.
72. Yanta J, Guyette FX, Doshi AA, Callaway CW, Rittenberger JC, Post Cardiac
Arrest Service: Renal dysfunction is common following resuscitation from
out-of-hospital cardiac arrest. Resuscitation 2013, 84:1371–1374.
73. Rosen SM, O’Connor K, Shaldon S: Haemodialysis disequilibrium. Br Med J
1964, 2:672–675.
74. Arieff AI, Massry SG, Barrientos A, Kleeman CR: Brain water and electrolyte
metabolism in uremia: effects of slow and rapid hemodialysis. Kidney Int
1973, 4:177–187.
75. Davenport A: Renal replacement therapy in the patient with acute brain
injury. Am J Kidney Dis 2001, 37:457–466.
76. Davenport A, Will EJ, Davison AM: Continuous vs. intermittent forms of
haemofiltration and/or dialysis in the management of acute renal failure
in patients with defective cerebral autoregulation at risk of cerebral
oedema. Contrib Nephrol 1991, 93:225–233.
77. Davenport A: Is there a role for continuous renal replacement therapies
in patients with liver and renal failure? Kidney Int Suppl 1999, 72:S62–S66.
78. Vinsonneau C, Camus C, Combes A, de Costa Beauregard MA, Klouche K,
Boulain T, Pallot JL, Chiche JD, Taupin P, Landais P, Dhainaut JF, Hemodiafe
Study Group: Continuous venovenous haemodiafiltration versus
intermittent haemodialysis for acute renal failure in patients with
multiple-organ dysfunction syndrome: a multicentre randomised trial.
Lancet 2006, 368:379–385.
79. Wu VC, Huang TM, Shiao CC, Lai CF, Tsai PR, Wang WJ, Huang HY, Wang KC,
Ko WJ, Wu KD, NSARF Group: The hemodynamic effects during sustained
low-efficiency dialysis versus continuous veno-venous hemofiltration for
uremic patients with brain hemorrhage: a crossover study. J Neurosurg
2013, 119:1288–1295.
80. Davenport A: Changing the hemodialysis prescription for hemodialysis
patients with subdural and intracranial hemorrhage. Hemodial Int 2013,
17:S22–S27.
81. Sherlock M, O’Sullivan E, Agha A, Behan LA, Rawluk D, Brennan P, Tormey
W, Thompson CJ: The incidence and pathophysiology of hyponatraemia
after subarachnoid haemorrhage. Clin Endocrinol (Oxf ) 2006, 64:250–254.
doi:10.1186/cc13907
Cite this article as: Nongnuch et al.: Brain–kidney crosstalk. Critical Care
2014 18:225.
